{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-248138","form_type":"8-K","ticker":"EQ","cik":"0001746466","company_name":"Equillium, Inc.","filed_at":"2024-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.442919+00:00","generated_at":"2026-05-30T07:32:18.650458+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Equillium announces Ono option lapse; pauses EQUATOR enrollment to review acceleration; cash runway into Q4 2025","bullets":["Ono's option to acquire itolizumab (EQ001) lapsed; Equillium retains all commercial rights to itolizumab.","EQUATOR Phase 3 study enrollment paused; company plans to accelerate topline data to Q1 2025 with ~150 patients.","Over 150 patients enrolled to date; orphan drug and fast track designations for first-line acute GVHD remain.","Biocon SA completed Phase 2 study of itolizumab in ulcerative colitis; topline data expected Q1 2025.","Company pauses EQ101 and EQ302 activities; cash runway expected into Q4 2025 with accelerated EQUATOR."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-248138","json":"https://secwatch.observer/filing/0001193125-24-248138.json","markdown":"https://secwatch.observer/filing/0001193125-24-248138.md","text":"https://secwatch.observer/filing/0001193125-24-248138.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746466/000119312524248138/0001193125-24-248138-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746466/000119312524248138/d787967d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T07:32:18.650458+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}